Abstracts - faqs.org

Abstracts

Business, international

Search abstracts:
Abstracts » Business, international

AstraZeneca shares decline 7.5% despite solid results, rosy outlook

Article Abstract:

AstraZeneca PLC saw its share value decline by 7.5% in spite of a strong performance in 1999 by the firm's pharmaceutical division. The company also provided a positive profit and sales forecast for the 2000 year.

Author: Moore, Stephen D.
Publisher: Dow Jones Publishing Co. (Europe)
Publication Name: Wall Street Journal. Europe
Subject: Business, international
ISSN: 0921-9986
Year: 2000

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


AstraZeneca shares fall 2.5% after cutting sales outlook

Article Abstract:

AstraZeneca PLC saw its share value decline by 2.5% after the company lowered its sales forecasts by the 2000 year. The company has experienced a slow 2000 third-quarter.

Author: Moore, Stephen D.
Publisher: Dow Jones Publishing Co. (Europe)
Publication Name: Wall Street Journal. Europe
Subject: Business, international
ISSN: 0921-9986
Year: 2000
Sales, profits & dividends, Finance, Forecasts and trends

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


AstraZeneca may remain volatile stock

Article Abstract:

AstraZeneca, an Anglo-Swedish drugmaker, saw its stocks dive 10% over the last 10 days, in spite of announcements of reserch on some very promising medicines. The decline is triggered by AstraZeneca's decision to repurchase one million of its own shares, and stocks are expected to remain volatile for a while.

Author: Moore, Stephen D.
Publisher: Dow Jones Publishing Co. (Europe)
Publication Name: Wall Street Journal. Europe
Subject: Business, international
ISSN: 0921-9986
Year: 1999
Sweden, Financial analysis, Statistical Data Included, Brief Article

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Subjects list: United Kingdom, Pharmaceutical industry, Drugs, Securities, AstraZeneca PLC, AZN
Similar abstracts:
  • Abstracts: Aetna plans to split into 2 businesses; asset sale is likely. Deluxe to split its operations, list tech units
  • Abstracts: Hilton Group's pretax profit soared a higher-than-expected 33% in half. Hilton profit increased 9.9% for the year
This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.
Some parts © 2025 Advameg, Inc.